ArsenalBio and TScan Shifted Biotech Strategies
Two biotech firms pivoted toward in vivo therapies, resulting in significant workforce reductions early in September 2026.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over shifting their financial research strategies?
On August 31 and September 2, 2026, ArsenalBio and TScan Therapeutics announced strategic shifts from ex vivo to in vivo cell therapy programs. Both companies downsized their operations as part of these new development priorities.
Why it matters
The companies shifted focus to in vivo technology, where immune cells are engineered inside the patient, citing broader potential for treating various diseases. TScan Therapeutics specifically moved to preserve resources due to a lack of capital required to finish late-stage clinical testing.
TScan Therapeutics eliminated approximately 75% of its workforce to accommodate its redirected focus. The company cited a lack of sufficient capital as the primary driver for pausing the Phase 3 ALLOHA-2 study.
The players
ArsenalBio
ArsenalBio is a biotechnology company focused on developing advanced cell therapies for the treatment of various diseases.
TScan Therapeutics
TScan Therapeutics is a biopharmaceutical company engaged in the development of T-cell receptor-based cancer therapies.
The details
TScan Therapeutics paused its Phase 3 ALLOHA-2 trial for TSC-101 to conserve funds while prioritizing its in vivo TCR-T candidates targeting PRAME and MAGE-A4. ArsenalBio concurrently shifted its pipeline toward in vivo CAR-T programs aimed at hematologic malignancies and autoimmune conditions.
Timeline
ArsenalBio announced its strategic pivot and staff cuts on August 31, 2026.
TScan Therapeutics paused trial enrollment and reduced its workforce on September 2, 2026.
Market Landscape
This pivot reflects a broader transition within the biotechnology sector from established ex vivo methods to emerging in vivo engineering techniques. The shift highlights a competitive environment where firms must increasingly trade long-term development bets for immediate capital efficiency.
The cancellation and pausing of clinical trials may limit the near-term availability of experimental treatment options for patients participating in these studies. Investors and industry followers should monitor how these companies reallocate their remaining resources toward new clinical goals.
The takeaway
The transition to in vivo therapies represents a significant technical evolution in how immune-based treatments are delivered to patients. Companies are increasingly prioritizing these scalable internal engineering methods to sustain operations in a capital-constrained market.
Further reading
For more on evolving research techniques, explore the latest updates in Biotech.
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over shifting their financial research strategies?
